Literature DB >> 2553197

Changing patterns in gastric adenocarcinoma.

G H Kampschöer1, T Nakajima, C J van de Velde.   

Abstract

A retrospective study was performed on gastric cancer patients admitted to the Cancer Institute Hospital, Tokyo, during the periods 1961-65 (n = 1181) and 1980-84 (n = 1473). The aim of the study was to see whether changes had occurred in gastric cancer patients over the years with respect to histology and tumour localization and, if so, how they compared with reports from the West. The proportion of proximally localized primary tumour increased from 17 to 27 per cent (P = 0.008), and signet-ring cell carcinoma increased from 2 to 22 per cent (P less than 0.001). These changes were not relative with regard to the declining incidence of intestinal tumours, but absolute. Patients with proximally localized tumours were generally in a more advanced stage of disease than those with distally localized tumours, and thus had poorer survival rates. However, after stratifying into stages, the difference in survival disappeared. The survival rate of patients with signet-ring cell carcinoma was not significantly different from that of patients with other gastric tumours (P greater than 0.05). The discrepancy between the survival rates of Japanese and western gastric cancer patients is attributed by some authors to tumour-related factors. However, we believe that the similar trends found with regard to tumour localization and histology point towards comparable tumour behaviour in the two different geographical areas.

Entities:  

Mesh:

Year:  1989        PMID: 2553197     DOI: 10.1002/bjs.1800760913

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  10 in total

Review 1.  Gastric cancer.

Authors:  P McCulloch
Journal:  Postgrad Med J       Date:  1996-08       Impact factor: 2.401

Review 2.  Current management of esophageal cancer.

Authors:  Xavier Benoit D'Journo; Pascal Alexandre Thomas
Journal:  J Thorac Dis       Date:  2014-05       Impact factor: 2.895

3.  [Survival of Gastric Cancer in Western Honduras Pilot study: 2002-2012].

Authors:  Eleazar Enrique Montalván; Daniela María Montalván; Samuel Alejandro Urrutia; Aída Argentina Rodríguez; Héctor Sandoval; Pedro Odair Sauceda; Columba Enedina Rodríguez; Ana Julia Melgar; Dagoberto Estévez; Douglas R Morgan; Karla Patricia Torres; Ricardo Leonel Domínguez
Journal:  Rev Med Hondur       Date:  2017

4.  Perspectives of surgery and multimodality treatment in gastric carcinoma.

Authors:  H J Meyer; J Jähne; H Wilke
Journal:  J Cancer Res Clin Oncol       Date:  1993       Impact factor: 4.553

5.  Comparison of factors influencing the prognosis of Japanese, German, and Dutch gastric cancer patients.

Authors:  J J Bonenkamp; C J van de Velde; G H Kampschöer; J Hermans; P Hermanek; M Bemelmans; D J Gouma; M Sasako; K Maruyama
Journal:  World J Surg       Date:  1993 May-Jun       Impact factor: 3.352

6.  Problem of proximal third gastric carcinoma.

Authors:  J R Siewert; K Böttcher; H J Stein; J D Roder; R Busch
Journal:  World J Surg       Date:  1995 Jul-Aug       Impact factor: 3.352

7.  Changing pattern of gastric cancer in Oxfordshire.

Authors:  E Rios-Castellanos; F Sitas; N A Shepherd; D P Jewell
Journal:  Gut       Date:  1992-10       Impact factor: 23.059

8.  Trend in incidence of gastric adenocarcinoma by tumor location from 1969-2004: a study in one referral center in Iran.

Authors:  Afshin Abdi-Rad; Siavash Ghaderi-sohi; Hosein Nadimi-Barfroosh; Sara Emami
Journal:  Diagn Pathol       Date:  2006-05-11       Impact factor: 2.644

9.  Improvements in diagnosis have changed the incidence of histological types in advanced gastric cancer.

Authors:  Y Ikeda; M Mori; T Kamakura; Y Haraguchi; M Saku; K Sugimachi
Journal:  Br J Cancer       Date:  1995-08       Impact factor: 7.640

10.  Are Japanese and European gastric cancer the same biological entity? An immunohistochemical study.

Authors:  J I Livingstone; W Yasui; E Tahara; C Wastell
Journal:  Br J Cancer       Date:  1995-10       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.